Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Abnormal analyte preeclampsia: do the second-trimester maternal serum analytes help differentiate preeclampsia subtypes?

Journal of Perinatology volume 33, pages 754–758 (2013)Cite this article

Subjects

Abstract

Objective:

To determine if serum screen analytes identify preeclamptic patients at risk for small-for-gestational age newborns, maternal laboratory abnormalities and preterm delivery (<37 weeks gestation).

Study Design:

Using a retrospective cohort of 102 preeclamptic patients, associations between serum screen analytes and newborn birth-weight percentile, gestational age (GA) at delivery and maternal pre-delivery laboratory abnormalities were evaluated using correlation coefficients and local polynomial regression.

Result:

Inhibin-A and maternal serum alpha fetoprotein were inversely correlated with newborn birth-weight percentile (−0.27, P=0.006; −0.35, P=0.00004) and delivery GA (r=−0.42, P<0.0001; r=−0.26, P=0.008) and positively correlated with pre-delivery aspartate aminotransferase (r=0.22, P=0.03; r=0.21, P=0.04) and lactate dehydrogenase (r=0.33, P=0.0007; r=0.29, P=0.004). A positive correlation was noted between both second-trimester beta human chorionic gonadotropin and estriol and maternal pre-delivery creatinine (0.28, P=0.004; 0.4, P<0.0001, respectively). Hundred percent of patients with ⩾2 abnormal analytes delivered before 37 weeks gestation.

Conclusion:

Preeclamptic patients with abnormal serum screen analytes are more likely to have small-for-gestational age newborns, deliver preterm and have pre-delivery laboratory abnormalities.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Haddad B, Sibai B . Expectant management in pregnancies with severe preeclampsia. Semin Perinatol 2009; 33: 143–151.

    Article  Google Scholar 

  2. National High Blood Pressure Education Program Working Group. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1–S22.

    Article  Google Scholar 

  3. American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia and eclampsia. ACOG Pract Bull 2002; 33.

  4. Phillips J, Janowaiak M, Badger G, Bernstain I . Evidence for distinct preterm and term phenotypes of preeclampsia. J Matern Fetal Neonatal Med 2010; 23 (7): 622–626.

    Article  CAS  Google Scholar 

  5. Ness R, Roberts J . Heterogeneous causes constituting the single syndrome of preeclampsia: A hypothesis and its implications. Am J Obstet Gynecol 1996; 175 (5): 1365–1370.

    Article  CAS  Google Scholar 

  6. Vatten L, Skjaerven R . In pre-elampsia more than one disease? Br J Obstet Gynaecol 2004; 111: 298–302.

    Article  Google Scholar 

  7. Von Dadelszen P, Magee L, Roberts J . Subclassification of preeclampsia. Hyperten Preg 2003; 22 (2): 143–148.

    Article  Google Scholar 

  8. Olsen RN, Woelkers D, Dunsmoor-Su R, Lacoursiere DY . Abnormal second trimester serum analytes are more predictive of preterm preeclampsia. Am J Obstet Gynecol 2012; 207 (3): 228.e1–7.

    Article  CAS  Google Scholar 

  9. Dugoff L . First and second trimester maternal serum screen markers for aneuploidy and adverse obstetrical outcomes. Obstet Gynecol 2010; 115 (5): 1052–1061.

    Article  Google Scholar 

  10. Spencer K, Cowans N, Avgidou K, Nicolaides K . First-trimester ultrasound and biochemical markers of aneuploidy and the risk of impending fetal death. Ultrasound Obstet Gynecol 2006; 28: 637–643.

    Article  CAS  Google Scholar 

  11. Spencer K, Cowans N, Nicolaides K . Low levels of maternal serum PAPP-A in the first trimester and the risk of preeclampsia. Prenat Diagn 2008; 28: 7–10.

    Article  Google Scholar 

  12. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CD et al. First trimester maternal PAPP-A and free beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population based screening study (The FaSTER trial). Am J Obstet Gynecol 2004; 191: 1446–1451.

    Article  CAS  Google Scholar 

  13. Krause TG, Christens P, Wohlfahrt J, Westergaard T, Norgaard-Pedersen B, Melbye M . Second trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy outcomes. Obstet Gynecol 2001; 97: 277–282.

    CAS  PubMed  Google Scholar 

  14. Spencer K . Second trimester prenatal screening for Down Syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcomes. Prenat Diagn 2000; 20: 652–656.

    Article  CAS  Google Scholar 

  15. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA et al. Quad screen as a predictor of adverse pregnancy outcomes. Obstet Gynecol 2005; 106: 260–267.

    Article  Google Scholar 

  16. Towner D, Gandhi S, El Kady D . Obstetric outcomes in women with elevated maternal serum human chorionic gonadotropin. Am J Obstet Gynecol 2006; 109: 1676–1682.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Daniel Gerlanc for expert assistance with creating graphical figures. This project was supported by the National Center for Research Resources grant number UL1 RR025752 and the National Center for Advancing Translational Sciences, National Institutes of Health, grant number UL1 TR000073.

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.

Author information

Authors and Affiliations

  1. Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA, USA

    A S Critchfield & A C Urato

  2. Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA

    J K Paulus

  3. MetroWest Medical Center, Framingham, MA, USA

    R Farez & A C Urato

Authors
  1. A S Critchfield
    View author publications

    Search author on:PubMed Google Scholar

  2. J K Paulus
    View author publications

    Search author on:PubMed Google Scholar

  3. R Farez
    View author publications

    Search author on:PubMed Google Scholar

  4. A C Urato
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to A S Critchfield.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Critchfield, A., Paulus, J., Farez, R. et al. Abnormal analyte preeclampsia: do the second-trimester maternal serum analytes help differentiate preeclampsia subtypes?. J Perinatol 33, 754–758 (2013). https://doi.org/10.1038/jp.2013.55

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/jp.2013.55

Keywords

Search

Advanced search

Quick links